Go Pro
→ This tiny piece of glass could be bigger than GPUs (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
$3.19
$5.41
$2.66
▼
$16.00
$60.90M1.3393,721 shs122,316 shs
ImageneBio, Inc. stock logo
IMA
ImageneBio
$5.69
$5.76
$3.94
▼
$15.79
$60.60M0.7612,474 shs32,305 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.49
$1.57
$1.34
▼
$3.35
$60.43M0.04144,456 shs105,108 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$0.44
$0.39
$0.30
▼
$1.24
$15.56M0.56722,688 shs159,672 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
0.00%+13.93%-8.33%-72.52%-65.33%
ImageneBio, Inc. stock logo
IMA
ImageneBio
0.00%+2.71%-3.72%+1.43%-61.21%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%-11.31%-11.83%-9.70%-54.43%
OSR Holdings, Inc. stock logo
OSRH
OSR
0.00%-1.12%+34.90%-21.98%-26.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
$3.19
$5.41
$2.66
▼
$16.00
$60.90M1.3393,721 shs122,316 shs
ImageneBio, Inc. stock logo
IMA
ImageneBio
$5.69
$5.76
$3.94
▼
$15.79
$60.60M0.7612,474 shs32,305 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.49
$1.57
$1.34
▼
$3.35
$60.43M0.04144,456 shs105,108 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$0.44
$0.39
$0.30
▼
$1.24
$15.56M0.56722,688 shs159,672 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
0.00%+13.93%-8.33%-72.52%-65.33%
ImageneBio, Inc. stock logo
IMA
ImageneBio
0.00%+2.71%-3.72%+1.43%-61.21%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%-11.31%-11.83%-9.70%-54.43%
OSR Holdings, Inc. stock logo
OSRH
OSR
0.00%-1.12%+34.90%-21.98%-26.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
2.50
Moderate Buy$19.75519.12% Upside
ImageneBio, Inc. stock logo
IMA
ImageneBio
2.00
Hold$30.00427.24% Upside
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.40
Hold$5.67280.31% Upside
OSR Holdings, Inc. stock logo
OSRH
OSR
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest OSRH, ELTX, IMA, and OKYO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/14/2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/13/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$7.00 ➝ $5.00
6/29/2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
OSR Holdings, Inc. stock logo
OSRH
OSR
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/18/2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
LADENBURG THALM/SH SH logo
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
6/16/2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
JonesTrading logo
JonesTrading
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
6/15/2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
Rodman & Renshaw logo
Rodman & Renshaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
6/15/2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$17.00 ➝ $23.00
6/10/2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$27.00
(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
N/AN/AN/AN/A$0.09 per shareN/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
$800K75.75N/AN/A$11.91 per share0.48
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A$0.30 per shareN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
$2.63M5.92N/AN/A$4.95 per share0.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
-$39.57M-$2.40N/AN/AN/AN/A-2,748.16%-151.12%N/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
-$45.35M-$5.79N/AN/AN/AN/A-38.99%-34.84%N/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$8.95MN/AN/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)
OSR Holdings, Inc. stock logo
OSRH
OSR
-$27.06M-$0.33N/AN/AN/A-363.26%-7.24%-5.41%N/A

Latest OSRH, ELTX, IMA, and OKYO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q4 2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$0.04N/AN/AN/AN/AN/A
8/5/2026Q2 2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
-$0.90-$0.63+$0.27-$0.63N/AN/A
5/13/2026Q1 2026
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A-$0.09N/A-$0.0880N/A$0.48 million
5/11/2026Q1 2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
-$0.49-$0.65-$0.16-$0.65N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
N/AN/AN/AN/AN/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
N/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
5.75
2.24
2.24
ImageneBio, Inc. stock logo
IMA
ImageneBio
N/A
21.47
21.47
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/A
2.43
2.43
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A
0.16
0.14

Institutional Ownership

CompanyInstitutional Ownership
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
35.03%
ImageneBio, Inc. stock logo
IMA
ImageneBio
75.00%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%
OSR Holdings, Inc. stock logo
OSRH
OSR
55.30%

Insider Ownership

CompanyInsider Ownership
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
28.65%
ImageneBio, Inc. stock logo
IMA
ImageneBio
2.22%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
OSR Holdings, Inc. stock logo
OSRH
OSR
36.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
N/A19.09 million13.62 millionNot Optionable
ImageneBio, Inc. stock logo
IMA
ImageneBio
7010.65 million10.42 millionNot Optionable
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
740.56 million24.15 millionNot Optionable
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A35.12 million22.16 millionN/A

Recent News About These Companies

OSR Health Inc.
August 9 at 2:09 PM  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/osrh/financials/cash-flow
OSRH OSR Health, Inc.
August 7 at 10:08 PM  |  seekingalpha.comhttps://seekingalpha.com/symbol/OSRH/sec-filings
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
August 7 at 3:00 PM  |  accessnewswire.comA
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform
August 3, 2026  |  accessnewswire.comA
OSR Health, Inc.: OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
August 1, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69186987-osr-health-inc-osr-health-secures-nasdaq-communication-loyalty-cvr-program-will-not-trigger-a-price-adjustment-200.htm
OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
July 31, 2026  |  accessnewswire.comA
OSR Health, A Message From the CEO
July 13, 2026  |  accessnewswire.comA
OSR Health Earnings Estimates, EPS & Revenue | NASDAQ:OSRH
July 6, 2026  |  benzinga.comhttps://www.benzinga.com/quote/OSRH/earnings
CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
July 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/correction-source-emerging-growth-research-170500642.html
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
July 2, 2026  |  accessnewswire.comA
OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares
June 25, 2026  |  accessnewswire.comA
OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do
June 22, 2026  |  accessnewswire.comA
OSR Holdings Rebrands as OSR Health in Name Change
June 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/osr-holdings-rebrands-as-osr-health-in-name-change?utm_source=marketbeat.com&utm_medium=referral
CEO Statement to Shareholders
June 3, 2026  |  accessnewswire.comA
OSR Holdings Secures VXM01 Rights in Asset Deal
June 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/osr-holdings-secures-vxm01-rights-in-asset-deal?utm_source=marketbeat.com&utm_medium=referral
OSR Holdings, Inc.: OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction
May 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68607121-osr-holdings-inc-osr-holdings-acquires-full-vxm01-intellectual-property-portfolio-in-dollar-30-million-transaction-200.htm
OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction
May 27, 2026  |  accessnewswire.comA
Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target
May 5, 2026  |  accessnewswire.comA
OSR Holdings, Inc. Common Stock (OSRH) SEC Filings
May 2, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/osrh/sec-filings
OSRH stock rockets 60% on $815M immunotherapy deal — retail bulls eye $1 mark for the stock
April 30, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/osrh-stock-rockets-60-on-815m-immunotherapy-deal-retail-bulls-eye-1-mark-for-the-stock/ar-AA2272q4

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
SK hynix logo above a robotic arm placing memory chips on a wafer in a server data center.
Why SK hynix Could Be the Best AI Chip Stock to Buy Now
By Thomas Hughes | July 29, 2026
Illustration of a quantum computing chip with gold wiring and cryogenic cooling components inside a circular chamber.
2 Quantum Stocks That Could Challenge IonQ’s Leadership
By Nathan Reiff | July 15, 2026
Netflix logo projected in a dim living room with a remote and Netflix mug on the coffee table.
Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
By Chris Markoch | July 18, 2026
Intel logo glowing above a detailed microchip surface in a high-tech semiconductor lab.
Intel Earnings Reveal Whether the Chip Selloff Created a Buy
By Chris Markoch | July 24, 2026
Elicio Therapeutics stock logo

Elicio Therapeutics NASDAQ:ELTX

$3.19 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$3.16 -0.04 (-1.10%)
As of 05:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

ImageneBio stock logo

ImageneBio NASDAQ:IMA

$5.69 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$5.60 -0.09 (-1.49%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$1.49 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$1.50 +0.01 (+0.67%)
As of 04:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

OSR stock logo

OSR NASDAQ:OSRH

$0.44 0.00 (0.00%)
Closing price 08/7/2026 03:59 PM Eastern
Extended Trading
$0.45 +0.01 (+2.26%)
As of 05:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas